Glenmark Generics Inc, the US subsidiary of Glenmark Generics, today said that the US Food and Drug Administration (USFDA) has given final approval for Rizatriptan Benzoate tablets, its generic version of Merck's Maxalt tablets.
The company has commenced shipping immediately after the approval, Glenmark said in a statement.
The approval is for the 5 mg and 10 mg of Rizatriptan.
According to IMS for the 12 month period ending September 2012, Rizatriptan Benzoate tablets achieved sales of $333 million.
Glenmark's current portfolio consists of 82 products and 46 ANDAs pending approval with the USFDA.
Glenmark stock was trading at Rs 539, 0.14% down from Tuesday's close.